Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Orchard Therapeutics logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Advanced Chart

Key Stats

Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

ORTX Stock Analysis - Frequently Asked Questions

Orchard Therapeutics plc (NASDAQ:ORTX) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($1.61) by $1.49. The firm had revenue of $1.24 million for the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

Shares of Orchard Therapeutics reverse split before market open on Friday, March 10th 2023.The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/15/2023
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Previous Symbol
NASDAQ:ORTX
CIK
1748907
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$150.66 million
Net Margins
-333.90%
Pretax Margin
-334.54%
Return on Equity
-74.94%
Return on Assets
-33.51%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.12
Quick Ratio
2.98

Sales & Book Value

Annual Sales
$22.66 million
Price / Sales
16.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.74 per share
Price / Book
2.16

Miscellaneous

Outstanding Shares
22,760,000
Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ORTX) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners